Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)

NCT02338843 is registered in ClinicalTrials.gov with La Jolla Pharmaceutical Company as lead sponsor.

NCT NCT02338843
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02338843 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Lead sponsor
La Jolla Pharmaceutical Company
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2015
Completion date
February 18, 2017
Enrollment
344 (actual)
Sites
115

Conditions

As the registry lists them; a condition with its own page is linked.

catecholamine-resistant hypotension (crh), distributive shock, high output shock, sepsis